Predictive Factors for Non-Response to Neoadjuvant Chemotherapy for Breast Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Neoadjuvant chemotherapy (NAC) can effectively downstage locally advanced breast cancer; however, in some cases the cancer remains clinically stable and in others, there is disease progression. Although factors predictive of the response to NAC have been established, those for a non-response remain unknown. This study investigated factors predicting a stable or progressive disease course, and the extent of the response, after NAC based on anthracycline and cyclophosphamide (AC), with or without taxane. Methods: Data were collected retrospectively by reviewing medical records of patients who received NAC for breast cancer using AC, with or without taxane between January 2013 and December 2017. Patients with clinically stable or progressive disease after NAC were compared statistically with those who achieved a partial or complete response. Results: In total, 297 patients received NAC with AC and 196 patients received AC followed by taxane. Of these, 45 (15.2%) and 64 (32.6%) patients respectively, showed no response (i.e., stable or progressive disease). Factors related to non-response after AC included large pretreatment tumor size, clinical T3 status, and high histologic grade. Factors related to non-response after taxane included clinical T3 status and estrogen receptor or progesterone receptor positivity. Conclusion: Clinical T3 stage, grade III histological grade, and estrogen or progesterone receptor positivity were predictors of no response to NAC for breast cancer.
Abstract
Purpose: Neoadjuvant chemotherapy (NAC) can effectively downstage locally advanced breast cancer; however, in some cases the cancer remains clinically stable and in others, there is disease progression. Although factors predictive of the response to NAC have been established, those for a non-response remain unknown. This study investigated factors predicting a stable or progressive disease course, and the extent of the response, after NAC based on anthracycline and cyclophosphamide (AC), with or without taxane. Methods: Data were collected retrospectively by reviewing medical records of patients who received NAC for breast cancer using AC, with or without taxane between January 2013 and December 2017. Patients with clinically stable or progressive disease after NAC were compared statistically with those who achieved a partial or complete response. Results: In total, 297 patients received NAC with AC and 196 patients received AC followed by taxane. Of these, 45 (15.2%) and 64 (32.6%) patients respectively, showed no response (i.e., stable or progressive disease). Factors related to non-response after AC included large pretreatment tumor size, clinical T3 status, and high histologic grade. Factors related to non-response after taxane included clinical T3 status and estrogen receptor or progesterone receptor positivity. Conclusion: Clinical T3 stage, grade III histological grade, and estrogen or progesterone receptor positivity were predictors of no response to NAC for breast cancer.
참고문헌 (14)
- Rastogi P, "Preoprerative chemotherapy : updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
- Von Minckwitz G, "Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes", J Clin Oncol, 30, pp.1796~1804 (2012)
- Kong X, "Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients", Eur J Cancer, 47, pp.2084~2090 (2011)
- Prevos R, "Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging : a systematic review", Eur Radiol, 22, pp.2607~2616 (2012)
- Eisenhauer E, "New response evaluation criteria in solid tumors : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
- Fisher B, "Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer", J Clin Oncol, 16, pp.2672~2685 (1998)
- Cortazar P, "Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC)", San Antonio Breast Cancer Symposium Conference, 72, pp.#S1~#S11 (2012)
- Guarneri V, "Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors", J Clin Oncol, 24, pp.1037~1044 (2006)
- Caudle AS, "Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer", J Clin Oncol, 28, pp.1821~1828 (2010)
- Loibl S, "Predictive factors for response to neoadjuvant therapy in breast cancer", Oncol Res Treat, 37, pp.563~568 (2014)
- Lee HJ, "Comparison of pathologic response evaluation systems after anthracycline with", without taxane-based neoadjuvant chemotherapy among different subtypes of breast cancers, 2015, pp.10, e0137885~
- Liedtke C, "Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer", J Clin Oncol, 26, pp.1275~1281 (2008)
- Mustacchi G, "The role of taxanes in triple-negative breast cancer : literature review", Drug Des Devel Ther, 9, pp.4303~4318 (2015)
- Tan QX, "Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy", Int J Clin Exp Pathol, 7, pp.6862~6870 (2014)